Noah is a neuroscience and translational medicine researcher at Harvard (HMS) & BCH, focusing on drug development and novel therapeutics. With experience in scientific due diligence and investment analysis, he has evaluated biotech innovations and assessed market positioning for emerging therapies. Beyond research, Noah founded LBS, and previously led teams at Amazon, optimizing operations and strategic decision-making. Excited to be part of the GAC 2025, he believes that fostering meaningful conversations between diverse stakeholders is key to strengthening the German-American partnership and addressing global challenges. In free time, Noah enjoys playing squash, exploring different cuisines, and diving deeper into biotech investing.